STOCKHOLM, Sweden--(BUSINESS WIRE)-- Anna Ahlberg, Vitrolife’s CFO for just over 4 years, has decided to terminate her employment at Vitrolife. Anna will begin to work at Global Health Partner, as Head of the company’s spine surgery business unit.
”Anna has done a great job at Vitrolife, amongst other things by organizing and structuring our finance activities so that they are at a recognized very high level. We wish her the very best of luck in her new position,” says Magnus Nilsson, CEO.
Anna Ahlberg will terminate her employment at Vitrolife in January 2009. The work of recruiting her successor is ongoing.
September 19, 2008 Kungsbacka, Sweden Magnus Nilsson CEO
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.
Vitrolife today has approximately 140 employees and the company’s products are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share is listed on the OMX Nordic Exchange Stockholm’s Nordic Small Cap list.
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Homepage: www.vitrolife.com.
